AIMC Topic: Intravitreal Injections

Clear Filters Showing 1 to 10 of 44 articles

Evaluating anti-VEGF responses in diabetic macular edema: A systematic review with AI-powered treatment insights.

Indian journal of ophthalmology
Recent advances in deep learning and machine learning have greatly increased the capabilities of extracting features for evaluating the response to anti VEGF treatment in patients with Diabetic Macular Edema (DME). In this review, we explore how thes...

Prediction of Reactivation After Antivascular Endothelial Growth Factor Monotherapy for Retinopathy of Prematurity: Multimodal Machine Learning Model Study.

Journal of medical Internet research
BACKGROUND: Retinopathy of prematurity (ROP) is the leading preventable cause of childhood blindness. A timely intravitreal injection of antivascular endothelial growth factor (anti-VEGF) is required to prevent retinal detachment with consequent visi...

Retinal Vascularization Rate Predicts Retinopathy of Prematurity and Remains Unaffected by Low-Dose Bevacizumab Treatment.

American journal of ophthalmology
PURPOSE: To assess the rate of retinal vascularization derived from ultra-widefield (UWF) imaging-based retinopathy of prematurity (ROP) screening as predictor of type 1 ROP and characterize the effect of anti-vascular endothelial growth factor (anti...

Anti-VEGF treatment outcome prediction based on optical coherence tomography images in neovascular age-related macular degeneration using a deep neural network.

Scientific reports
Age-related macular degeneration (AMD) is a major cause of blindness in developed countries, and the number of affected patients is increasing worldwide. Intravitreal injections of anti-vascular endothelial growth factor (VEGF) are the standard thera...

Artificial intelligence-based analysis of retinal fluid volume dynamics in neovascular age-related macular degeneration and association with vision and atrophy.

Eye (London, England)
BACKGROUND/OBJECTIVES: To characterise morphological changes in neovascular age-related macular degeneration (nAMD) during anti-angiogenic therapy and explore relationships with best-corrected visual acuity (BCVA) and development of macular atrophy (...

Approved AI-based fluid monitoring to identify morphological and functional treatment outcomes in neovascular age-related macular degeneration in real-world routine.

The British journal of ophthalmology
AIM: To predict antivascular endothelial growth factor (VEGF) treatment requirements, visual acuity and morphological outcomes in neovascular age-related macular degeneration (nAMD) using fluid quantification by artificial intelligence (AI) in a real...